FDA denies approval for Actavis hypertension treatment

(Reuters) - Generic drug maker Actavis Plc said the U.S. health regulator denied an approval for its hypertension treatment, a fixed-dose combination of nebivolol and valsartan. The company said it would review the U.S. Food and Drug Administration's complete response letter and decide on appropriate next steps. The regulator issues a complete response letter when a new or generic treatment cannot be approved in its current form. Actavis did not give any further details on the contents of the letter. ...



via Health News Headlines - Yahoo News http://ift.tt/1x57EdQ